Compare · INDV vs JNJ
INDV vs JNJ
Side-by-side comparison of Indivior Pharmaceuticals Inc. (INDV) and Johnson & Johnson (JNJ): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both INDV and JNJ operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- JNJ is the larger of the two at $594.63B, about 116.4x INDV ($5.11B).
- Over the past year, INDV is up 162.5% and JNJ is up 49.9% - INDV leads by 112.6 points.
- JNJ has been more active in the news (8 items in the past 4 weeks vs 2 for INDV).
- JNJ has more recent analyst coverage (25 ratings vs 7 for INDV).
- Company
- Indivior Pharmaceuticals Inc.
- Johnson & Johnson
- Price
- $40.91+1.72%
- $246.98-2.68%
- Market cap
- $5.11B
- $594.63B
- 1M return
- +6.41%
- +2.55%
- 1Y return
- +162.53%
- +49.91%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 2
- 8
- Recent ratings
- 7
- 25
Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Latest INDV
- Chief Scientific Officer Heidbreder Christian sold $764,628 worth of shares (18,586 units at $41.14) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 209,337 units (SEC Form 4)
- Chief Executive Officer Ciaffoni Joseph converted options into 1,266,903 shares and covered exercise/tax liability with 612,549 shares, increasing direct ownership by 481% to 790,330 units (SEC Form 4) to cover taxes
- Barclays initiated coverage on Indivior with a new price target
- Chief Scientific Officer Heidbreder Christian sold $707,383 worth of shares (18,586 units at $38.06) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 227,923 units (SEC Form 4)
- Chief Financial Officer Preblick Ryan sold $1,357,200 worth of shares (36,000 units at $37.70) as part of a pre-agreed trading plan, decreasing direct ownership by 11% to 284,751 units (SEC Form 4)
- New Studies Show Adherence to Monthly Injectable Buprenorphine is Associated with Relapse Reduction and Lower Healthcare Utilization
- Indivior Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders
- Director Thompson Juliet covered exercise/tax liability with 1,117 shares and was granted 6,518 shares, increasing direct ownership by 71% to 12,973 units (SEC Form 4) (withholding tax)
- Director Humphreys Keith was granted 6,518 shares, increasing direct ownership by 68% to 16,042 units (SEC Form 4)
- Director Kingsley Stuart A was granted 6,518 shares, increasing direct ownership by 117% to 12,100 units (SEC Form 4)
Latest JNJ
- Johnson & Johnson filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2026
- Johnson & Johnson reports Q2 2026 results, raises 2026 outlook
- Johnson & Johnson Announces FDA Approval for the Dual Energy THERMOCOOL SMARTTOUCH SF Platform
- Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity
- Johnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis
- SEC Form 11-K filed by Johnson & Johnson
- SEC Form 11-K filed by Johnson & Johnson
- Johnson & Johnson Invests more than $1 Billion to Strengthen U.S. Vision Manufacturing in Jacksonville, Florida
- New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma